Centocor Inc. and its partner Schering-Plough Corp. said their investigational rheumatoid arthritis drug golimumab (CNTO 148), a next-generation human antitumor necrosis factor (TNF)-alpha monoclonal antibody, met its primary endpoint in three separate Phase III studies. (BioWorld Today) Read More
